Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
This study explores valuable potential AEs of belimumab at the SOC and PT levels, respectively. To provide a reference for decision-making on belimumab, including its use in children, and to promote rational clinical dosing.
Authors
- Ruxu You (ORCID: https://orcid.org/0000-0003-3057-4462)
- Mingming Li (ORCID: https://orcid.org/0009-0004-6650-9974)
- Cong Wang (ORCID: https://orcid.org/0000-0002-8222-2867)
- Jie Li
- Ziming Zheng (ORCID: https://orcid.org/0000-0002-2969-4582)
Institutions
- Union Hospital (HK)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1080/14740338.2024.2430302
- Citations
- 1
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province